Brief: Xspray Pharma Says FDA Accepts New Drug Application For Xs003 (Nilotinib)
21/10/2025 10:52
Oct 21 (Reuters) - XSpray Pharma AB (publ) XSPRAY.ST: FDA ACCEPTS NEW DRUG APPLICATION FOR XS003 (NILOTINIB) FOR THE TREATMENT OF CML – PDUFA DATE SET FOR JUNE 18, 2026 Source text: ID:nMFN99sVLB Further company coverage: XSPRAY.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003